---

$18.46

-1.5700 ( -7.84% ) 251.0K

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Open	$18.46
Previous Close	$20.03
Volume	251.0K
Market Cap	$661.52M
Day Range	$17.94 - $20.48
52 Week Range	$2.15 - $28.44
Shares Outstanding	35.09M
Change %	-7.84%
Net Change	▼ -1.5700
Insider Ownership	-0.01%
Exchange	NYSE
Sector	Healthcare
Industry	Biotechnology
IPO Year	2024
Country	United States
Underwriter	Jefferies, TD Cowen, Stifel, William Blair, Baird, more

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-02-07	Sale	-588898.00	Cox Christopher Nixon
2024-02-07	Sale	-39259.00	Chen Po Yu (Jeff)
2024-02-07	Sale	-23917.00	York Gwill
2024-02-07	Buy	1563.00	Smith Nicholas Conrad
2024-02-07	Buy	11777.00	Etkin Amit
2024-02-05	Sale	-30574.00	Manji Husseini
2024-02-05	Sale	-30574.00	Chen Po Yu (Jeff)
2024-02-05	Sale	-30574.00	Cox Christopher Nixon
2024-02-05	Sale	-30574.00	Dreyfus Andrew
2024-02-05	Sale	-30574.00	York Gwill